Treatment versus Transplant for Challenging Hematologic Disorders

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 72-78

  Parker, Charles J ^a   Brodsky, Robert A ^b   Levine, John E ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG THERAPY; ECULIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLOOD TRANSFUSION; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; DIFFERENTIAL DIAGNOSIS; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KOSTMANN SYNDROME; LEUKEMIA; METHODOLOGY; MUSCULOSKELETAL DISEASE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OSTEOPENIA; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; THERAPY; THROMBOPHILIA; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; LEUKEMIA; METHODS; MYELODYSPLASTIC SYNDROMES; THERAPEUTIC USE; THERAPY;

EID: 64749112147     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.001     Document Type: Article

References (41)

1. Parker C.J. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 35 (2007) 523-533
2. Kinoshita T., Inoue N., and Takeda J. Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Adv Immunol 60 (1995) 57-103
3. Parker C., Omine M., Richards S., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 3699-3709
4. Murakami Y., Kinoshita T., Maeda Y., Nakano T., Kosaka H., and Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood 94 (1999) 2963-2970
5. Inoue N., Izui-Sarumaru T., Murakami Y., et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108 (2006) 4232-4236
6. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 (2006) 1233-1243
7. Hillmen P., Muus P., Dührsen U., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007) 4123-4128
8. Sugimori C., Chuhjo T., Feng X., et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 (2006) 1308-1314
9. Ishiyama K., Chuhjo T., Wang H., Yachie A., Omine M., and Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 102 (2003) 1211-1216
10. Endo M., Beatty P.G., Vreeke T.M., Wittwer C.T., Singh S.P., and Parker C.J. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood 88 (1996) 742-750
11. Bemba M., Guardiola P., Garderet L., et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 105 (1999) 366-368
12. Raiola A.M., Van Lint M.T., Lamparelli T., et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 85 (2000) 59-62
13. Hegenbart U., Niederwieser D., Forman S., et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 9 (2003) 689-697
14. Takahashi Y., McCoy J.P., Carvallo C., et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 103 (2004) 1383-1390
15. Woodard P., Wang W., Pitts N., et al. Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant 27 (2001) 589-592
16. Ware R.E., Hall S.E., and Rosse W.F. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 325 (1991) 991-996
17. van den Heuvel-Eibrink M.M., Bredius R.G.M., te Winkel M.L., et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in The Netherlands. Br J Haematol 128 (2005) 571-577
18. Brodsky R.A., and Jones R.J. Aplastic anaemia. Lancet 365 (2005) 1647-1656
19. Brodsky R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern. Med 148 (2008) 587-595
20. Brodsky R.A., Mukhina G.L., Li S., et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 114 (2000) 459-466
21. Matsui W.H., Brodsky R.A., Smith B.D., Borowitz M.J., and Jones R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20 (2006) 458-462
22. Mukhina G.L., Buckley J.T., Barber J.P., Jones R.J., and Brodsky R.A. Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol 115 (2001) 476-482
23. Wang H., Chuhjo T., Yasue S., Omine M., and Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 100 (2002) 3897-3902
24. Rosenfeld S., Follmann D., Nunez O., and Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289 (2003) 1130-1135
25. Brodsky R.A., Sensenbrenner L.L., Smith B.D., et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern. Med 135 (2001) 477-483
26. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 108 (2006) 1485-1491
27. Skokowa J., Germeshausen M., Zeidler C., and Welte K. Severe congenital neutropenia: inheritance and pathophysiology. Curr Opin Hematol 14 (2007) 22-28
28. Boxer L.A., and Newburger P.E. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 49 (2007) 609-614
29. Carlsson G., Andersson M., Pütsep K., et al. Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia. Acta Pædiatr 95 (2006) 1526-1532
30. Dale D.C., Bolyard A.A., Schwinzer B.G., et al. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther 3 (2006) 220-231
31. Berliner N. Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis. Blood 111 (2008) 5427-5432
32. Ancliff P.J., Gale R.E., Liesner R., Hann I.M., and Linch D.C. Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. Blood 98 (2001) 2645-2650
33. Klein C., Grudzien M., Appaswamy G., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 39 (2007) 86-92
34. Dale D.C., Bonilla M.A., Davis M.W., et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81 (1993) 2496-2502
35. Rosenberg P.S., Alter B.P., Bolyard A.A., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107 (2006) 4628-4635
36. Germeshausen M., Skokowa J., Ballmaier M., Zeidler C., and Welte K. G-CSF receptor mutations in patients with congenital neutropenia. Curr Opin Hematol 15 (2008) 332-337
37. Zeidler C., Welte K., Barak Y., et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 95 (2000) 1195-1198
38. Mino E., Kobayashi R., Yoshida M., Suzuki Y., Yamada M., and Kobayashi K. Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia. Bone Marrow Transplant 33 (2004) 969-971
39. Fukano R., Nagatoshi Y., Shinkoda Y., et al. Unrelated bone marrow transplantation using a reduced-intensity conditioning regimen for the treatment of Kostmann syndrome. Bone Marrow Transplant 38 (2006) 635-636
40. Ferry C., Ouachée M., Leblanc T., et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant 35 (2005) 45-50
41. Choi S.W., Boxer L.A., Pulsipher M.A., et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 35 (2005) 473-477